Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Acquisition Of Corus Adds Respiratory Disease Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.

You may also be interested in...



Gilead Hopes To Dodge New Trial With CF Antibiotic

FDA’s complete response finds the Cayston NDA not approvable as is.

Gilead Hopes To Dodge New Trial With CF Antibiotic

FDA’s complete response finds the Cayston NDA not approvable as is.

Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports

Convenience and tolerability benefits could position aztreonam lysine as best-in-class.

Related Content

Topics

UsernamePublicRestriction

Register

PS064554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel